<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02356913</url>
  </required_header>
  <id_info>
    <org_study_id>F-IN112</org_study_id>
    <secondary_id>NIC/2013/1012</secondary_id>
    <nct_id>NCT02356913</nct_id>
  </id_info>
  <brief_title>Comparison of Pharmacokinetic Profiles of 3 New Nicotine Gum Formulations With a Reference Gum</brief_title>
  <official_title>A Pilot, Open Label, Randomised, Single Dose, Four-Period, Four-Treatment, Four-Sequence, Four Way Crossover Comparative Pharmacokinetic Study of Three Different 4 mg Nicotine Chewing Gum Test Formulations of Fertin Pharma A/S, Denmark With Nicorette Freshmint 4 mg Medicated Chewing Gum of McNeil Denmark ApS as Reference Formulation in Healthy, Adult, Human Smokers Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fertin Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fertin Pharma A/S</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the pharmacokinetic (PK) profiles and assess
      bioequivalence between three new nicotine gum formulations and a reference nicotine gum in
      healthy smokers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum observed nicotine concentration in plasma (Cmax)</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration vs. time curve until the last measurable concentration (AUC0-t)</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration vs. time curve until infinity (AUC∞)</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>12 hours from start of product administration</time_frame>
    <description>The time of occurrence of Cmax following product administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel</measure>
    <time_frame>12 hours</time_frame>
    <description>The apparent Terminal Elimination Rate Constant of nicotine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T½</measure>
    <time_frame>12 hours</time_frame>
    <description>The apparent Terminal Elimination Half-life of nicotine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of nicotine released from the gum during 30 minutes of chewing</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Gum A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg nicotine gum; single dose; chewed 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gum B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg nicotine gum; single dose; chewed 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gum C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg nicotine gum; single dose; chewed 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicorette Freshmint</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mg nicotine gum; single dose; chewed 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine gum</intervention_name>
    <arm_group_label>Gum A</arm_group_label>
    <arm_group_label>Gum B</arm_group_label>
    <arm_group_label>Gum C</arm_group_label>
    <arm_group_label>Nicorette Freshmint</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, adult, human smoker volunteers of any race within the age between 18 to 55
             years.

          -  Willingness to provide informed consent to participate in the study

          -  Body Mass Index (BMI)&gt; 18.5 kg/m2 to &lt; 28.0 kg/m2.

          -  Smoke 5-10 cigarettes per day continuously for the last three (3) months

          -  Exhaled carbon monoxide ≥ 10 ppm at screening visit

          -  Successfully complete the training session

          -  Medically healthy subjects with clinically normal laboratory profiles, vital signs and
             ECGs as deemed by the Clinical Investigator

          -  Subject who are not in the process of quitting smoking

          -  Hemoglobin: ≥12.0 gm% for male and ≥11.5 gm% for female

          -  Absence of disease markers of HIV I &amp; II, HBsAg, HCVAb and P24 antigen test.

          -  Females of childbearing age must be practicing an acceptable form of birth control for
             at least six months before screening and continue practicing an acceptable form of
             birth control during the study, unless they have had bilateral oophorectomy or tubal
             ligation or male partner has had vasectomy.

          -  Females of childbearing age agree to use acceptable form of birth control until the
             drug is washed out from the body i.e. 3 days after last dosing, unless male partner
             has had vasectomy.

          -  Absence of significant disease or clinically significant abnormal laboratory values on
             the laboratory evaluations, medical history or physical examination during the
             screening.

          -  Have a normal 12-lead ECG or one with abnormality considered clinically insignificant.

          -  Have a normal chest X-ray (P. A. view).

          -  Comprehension of the nature and purpose of the study and willingness to comply with
             the requirements of the entire procedure.

          -  Negative Breath alcohol test at every check in.

          -  Negative serum β-HCG at the time of screening and at every check in (for females
             only).

          -  Negative urine drug of abuse test (Barbiturates, Benzodiazepines, Opioids, Cocaine,
             Cannabinoids and Amphetamine, etc.) at every check-in. (This test will be done at the
             clinical facility).

          -  Willing to use Nicotine chewing gum during the study

        Exclusion Criteria:

          -  History or presence of; drug abuse within the past year; hypersensitivity or
             idiosyncratic reaction to Nicotine or the resin of the gum preparation; any form of
             oral and/or pharyngeal inflammation; any form of oral lesions and/or gum disease or
             temperomandibular joint dysfunction; dentures or any dental work that could, in the
             opinion of the Investigator, affect the conduct of the study (including missing
             molars);

          -  Any major illness in the last three months or any significant ongoing chronic medical
             illness.

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or
             psychiatric disease.

          -  Active deep vein thrombosis, arterial thromboembolic disorders or a history of these
             conditions

          -  History of or current gastro-intestinal diseases influencing drug absorption.

          -  Subjects who had been on a special diet (for whatever reason) during the 28 days prior
             to the first dose and throughout the study.

          -  Those who have used tobacco or nicotine containing products within 24 hours prior to
             the study drug administration on each study day.

          -  Subjects with carbon monoxide levels greater than or equal to 8 ppm in the morning
             prior to dosing.

          -  Suffer from xerostomia (dry mouth).

          -  Subjects using any smoking cessation aids such as nicotine replacement therapy (NRT),
             buproprion or varenicline during the last 3 months.

          -  History of neuropsychiatric diseases.

          -  History of breast cancer, endometrial cancer or other estrogen-dependent neoplasia,
             endometriosis and undiagnosed vaginal bleeding (for females only).

          -  Consumption of xanthine containing food and beverages [chocolates, tea, coffee or cola
             drinks] less than 48.0 hours prior to check in.

          -  Consumption of grapefruit/ Seville orange, grapefruit/ Seville orange juice products
             and poppy- containing food and beverages less than 48.0 hours prior to every check in.

          -  History of alcoholism (more than two years), moderate drinkers (more than three drinks
             per day) or having consumed alcohol less than 48.0 hours prior to check in.

          -  Participation in any clinical trial within last three months.

          -  History of difficulty with donating blood or difficulty in accessibility of veins in
             left or right arm.

          -  Donation of blood (one unit or 350 mL or more) within last three months prior to
             receiving the first dose of investigational products.

          -  Use of any prescription drug therapy or over the counter (OTC) drugs or herbal
             products within two weeks prior to receiving the first dose of study medication and
             during the study [includes catecolamines, theophylline, clozapine and ropinirol].

          -  Pregnant women

          -  Breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tejas Acharya, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Synchron Research Services Pvt. Ltd.</affiliation>
  </overall_official>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2015</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

